Triple therapy tops dual therapy in COPD in ETHOS study

There is more evidence for the benefit of triple therapy in patients with moderate to severe COPD. The ETHOS trial, published in the NEJM, comprised 8,509 patients with COPD from 26 countries including Australia. Patients with a diagnosis of active asthma within the past five to 10 years were excluded. Patients were randomised to one ...

Already a member?

Login to keep reading.

© 2021 the limbic